These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 12778059

  • 1. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
    Verra N, Jansen R, Groenewegen G, Mallo H, Kersten MJ, Bex A, Vyth-Dreese FA, Sein J, van de Kasteele W, Nooijen WJ, de Waal M, Horenblas S, de Gast GC.
    Br J Cancer; 2003 May 06; 88(9):1346-51. PubMed ID: 12778059
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM.
    Cancer; 2000 Mar 15; 88(6):1317-24. PubMed ID: 10717612
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.
    Garcia JA, Mekhail T, Elson P, Wood L, Bukowski RM, Dreicer R, Rini BI.
    BJU Int; 2012 Jan 15; 109(1):63-9. PubMed ID: 21244601
    [Abstract] [Full Text] [Related]

  • 9. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy.
    Verra N, de Jong D, Bex A, Batchelor D, Dellemijn T, Sein J, Nooijen W, Meinhardt W, Horenblas S, de Gast G, Vyth-Dreese F.
    Eur Urol; 2005 Sep 15; 48(3):527-33. PubMed ID: 16115526
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
    Lissoni P, Bordin V, Vaghi M, Fumagalli L, Bordoni A, Mengo S, Bucovec R, Fumagalli E, Malugani F, Ardizzoia A, Giani L, Gardani GS, Tancini G.
    Anticancer Res; 2002 Sep 15; 22(2B):1061-4. PubMed ID: 12168901
    [Abstract] [Full Text] [Related]

  • 12. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L, Fenchel K, Weidmann E, Enzinger HM, Jahn B, Jonas D, Mitrou PS.
    Cancer; 1993 Sep 01; 72(5):1733-42. PubMed ID: 8348502
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
    Gause BL, Sznol M, Kopp WC, Janik JE, Smith JW, Steis RG, Urba WJ, Sharfman W, Fenton RG, Creekmore SP, Holmlund J, Conlon KC, VanderMolen LA, Longo DL.
    J Clin Oncol; 1996 Aug 01; 14(8):2234-41. PubMed ID: 8708712
    [Abstract] [Full Text] [Related]

  • 16. Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
    Kudo-Saito C, Wansley EK, Gruys ME, Wiltrout R, Schlom J, Hodge JW.
    Clin Cancer Res; 2007 Mar 15; 13(6):1936-46. PubMed ID: 17363550
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A.
    Cancer Res; 2001 Nov 01; 61(21):7925-33. PubMed ID: 11691814
    [Abstract] [Full Text] [Related]

  • 19. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
    George S, Hutson TE, Mekhail T, Wood L, Finke J, Elson P, Dreicer R, Bukowski RM.
    Cancer Chemother Pharmacol; 2008 Jul 01; 62(2):347-54. PubMed ID: 17909807
    [Abstract] [Full Text] [Related]

  • 20. Granulocyte-macrophage colony-stimulating factor and interferon-alpha 2B in patients with advanced renal cell carcinoma.
    Lümmen G, Sperling H, Luboldt H, Otto T, Rübben H.
    Urol Int; 1998 Jul 01; 61(4):215-9. PubMed ID: 10364752
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.